Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)

NCT01215227 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01215227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01215227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 3
Overall status
Terminated
Start date
November 18, 2010
Completion date
July 16, 2013
Enrollment
839 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson disease, parkinson disease